Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
Molecular Autism volume 12, Article number: 44 (2021)
Correction to: Molecular Autism (2021) 12:38 https://doi.org/10.1186/s13229-021-00447-5
Following publication of the original article , the authors pointed out that the part of the text in Methods part was incorrectly stipulated and should read as follows:
We were unable to produce or obtain SF-rich preparations for this study like those used in our previous study . Based on prior testing of alternative preparations [25–27], we used commercially available crushable tablets containing broccoli seed and sprout extracts as a source of GR (equivalent to 34 µmol GR calculated to yield at least ~ 15 µmol SF) and active myrosinase enzyme. Tablets commercially produced as Avmacol® were provided by Nutramax Laboratories, Inc., Edgewood, MD. Placebo tablets, identical in size and similar in appearance to the active tablets, contained microcrystalline cellulose, red, yellow and black coloring and magnesium stearate, and were produced by Dr. Stephen Hoag, University of Maryland Department of Pharmacy.
Zimmerman AW, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021;12:38. https://doi.org/10.1186/s13229-021-00447-5.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zimmerman, A.W., Singh, K., Connors, S.L. et al. Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Molecular Autism 12, 44 (2021). https://doi.org/10.1186/s13229-021-00451-9